BioNTech Results Presentation Deck

Third Quarter 2020 Financial Results (unaudited) - Balance Sheet Balance Sheet Position 2020 Full Year Financial Guidance 23 I Cash and cash equivalents of €990.5 million ($1,159.7 million¹) as of September 30, 2020 On July 27, 2020, BioN Tech closed an underwritten offering of 5,500,000 American Depositary Shares ("ADSs"), each representing one of BioNTech's ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of €435.0 million ($511.5 million¹) • On August 28, 2020, BioNTech and a fund associated with Temasek closed a €100.0 million ($119.2 million ¹) investment in a 4-year mandatory convertible note. Temasek and another accredited investor contributed a private investment of €123.9 million ($146.0 million¹) in ordinary shares ● On September 15, 2020 BioNTech secured grant funding of up to €375.0 million ($439.1 million¹) in milestone-based funding from the BMBF2 to support and accelerate the BNT162 vaccine program execution. As funding for the grant occurs subsequent to quarter end and is subject to draw downs, this funding is not reflected in the cash and cash equivalent. balance as of September 30, 2020 BioNTech expects net cash used in operating activities and for purchases of property, plant and equipment to be within the previously guided range of €450 million and €600 million for the full year 2020 - likely to hit upper end of range due to acquisition of manufacturing facility Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020 2 German Federal Ministry of Education (Bundesminsterium für Bildung und Forschung) BIONTECH

View entire presentation